Peramivir

Paul G. Auwaerter, M.D., Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID

INDICATIONS

INDICATIONS

INDICATIONS

FDA

FDA

FDA

  • FDA-approved for uncomplicated influenza in patients ≥ 6 months with symptoms present for less than 2 days.

NON-FDA APPROVED USES

NON-FDA APPROVED USES

NON-FDA APPROVED USES

  • Treatment of influenza for hospitalized adult and pediatric patients for whom therapy with an IV anti-influenza drug is needed.
    • Hospitalized influenza when oral/enteric oseltamivir cannot be tolerated or reliably absorbed (off-label).
      • Clinical benefit of peramivir has not been established in hospitalized patients.

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.